…All slides developed by NeuroSens in collaboration with Dr. Daniel Selchen. The slide deck is open access, and no permissions are required prior to use. As a courtesy, we would like to ask that you provide us with feedback after your presentation(s). This will help us to fine-tune free educational resources that NeuroSens develops in the future. Click here to complete the feedback questionnaire WEBINAR (full recording) – Selected Highlights from…
…ths after a relapse; PIRA was defined as sustained disability in a relapse-free patient. During the median 12-year follow-up, 35% experienced a relapse and 39% had new MRI activity despite their initial NEDA status. Overall, 26% of patients experienced an accrual of disability: 14% was attributed to RAW and 12% to PIRA. The median time from treatment start to RAW or PIRA was 10 and 9 years, respectively. There was no difference in the median EDSS…
…ohort. Comorbid NMOSD patients were six-fold more likely to have a poor outcome compared to non-comorbid patients. RIS: stratifying risk of progression An analysis of the RelevarEM MS/NMOSD registry in Argentina (n=88) reported that patients with radiologically isolated syndrome with two or three risk factors were at high risk of progression to CIS/MS (Rojas et al. ECTRIMS 2021; abstracts P006 and P009). Over the 40-month follow-up period, 44.3% s…
…es (n=322). Results: There were reservations about a PPMS diagnosis in 52% Common problems were an incomplete diagnostic work-up, early reports of demyelinating events, failure to exclude alternative diagnoses, lack of laboratory testing, not meeting McDonald 2017 criteria, and concomitant conditions that blurred the MS clinical course. Conclusion: A thorough medical history and clinical work-up are needed. P024 – Long-term efficacy of satralizuma…
…l inflammatory activity declines due to immunosenescence, and disability becomes evident as compensatory mechanisms are exhausted. Despite these findings of early PIRA onset, one proposed definition of SPMS requires an EDSS score of 4.0 before a diagnosis can be made (Lorscheider et al. Brain 2016;139:2395-2405), which is likely to result in a considerable delay. The OPERA analysis suggests that the onset of progression frequently occurs in patien…